1
|
Imounga LM, Drak Alsibai K, Plenet J, Wang Q, Virjophe-Cenciu B, Couppie P, Sabbah N, Adenis A, Nacher M. The Singular Epidemiology of Plasmacytoma and Multiple Myeloma in French Guiana. Cancers (Basel) 2023; 16:178. [PMID: 38201605 PMCID: PMC10777965 DOI: 10.3390/cancers16010178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 12/22/2023] [Accepted: 12/23/2023] [Indexed: 01/12/2024] Open
Abstract
BACKGROUND The objective was to review a decade of plasmacytoma (PC) and multiple myeloma (MM) data from French Guiana, and to study its spatial and temporal trends. METHODS This was a retrospective study of MM and PC between January 2005 and December 2014 using cancer registry data, including age-standardized incidence and mortality rates. RESULTS There were 110 cases of PC and MM (62 women and 48 men), representing the eighth most frequent malignancy in French Guiana. PC and MM were much more common in females. In men, 79% of cases occurred at ≥55 years, and in women, 90% of cases occurred at ≥50 years. The median age at diagnosis was 60 years for men and 66 years for women, while it was 72 years for men and 75 years for women in mainland France. The incidence rate standardized to the world population was 5.9 patients of PC and MM per 100,000 men/year and 7.8 per 100,000 women/year. CONCLUSIONS In our territory, the incidence of PC and MM was higher and patients were diagnosed at a substantially younger age than in mainland France. Women had a greater incidence than men, and there was an increasing temporal trend of incidence among women. African ancestry and the frequency of obesity, notably among women, could have contributed to this observation.
Collapse
Affiliation(s)
- Laure Manuella Imounga
- Registre des Cancers de Guyane (RCan Guyane), Département Research, Innovation et Santé Publique (DRISP), Cayenne Hospital Center Andrée Rosemon, 97300 Cayenne, French Guiana; (L.M.I.); (Q.W.); (A.A.)
| | - Kinan Drak Alsibai
- Registre des Cancers de Guyane (RCan Guyane), Département Research, Innovation et Santé Publique (DRISP), Cayenne Hospital Center Andrée Rosemon, 97300 Cayenne, French Guiana; (L.M.I.); (Q.W.); (A.A.)
- Département Formation Recherche (DFR) en Santé, Université de Guyane, 97300 Cayenne, French Guiana;
- Service d’Anatomie et de Cytologie Pathologiques, Cayenne Hospital Center Andrée Rosemon, 97300 Cayenne, French Guiana
- Centre d’Investigation Clinique (CIC, INSERM 1424), Cayenne Hospital Center Andrée Rosemon, 97300 Cayenne, French Guiana
| | - Juliette Plenet
- Union Régionale des Professionnels de Santé (URPS), 97300 Cayenne, French Guiana;
| | - Qiannan Wang
- Registre des Cancers de Guyane (RCan Guyane), Département Research, Innovation et Santé Publique (DRISP), Cayenne Hospital Center Andrée Rosemon, 97300 Cayenne, French Guiana; (L.M.I.); (Q.W.); (A.A.)
| | | | - Pierre Couppie
- Département Formation Recherche (DFR) en Santé, Université de Guyane, 97300 Cayenne, French Guiana;
- Service de Dermatologie, Cayenne Hospital Center AndréeRosemon, 97300 Cayenne, French Guiana
| | - Nadia Sabbah
- Service d’Endocrinologie et Diabétologie, Cayenne Hospital Center Andrée Rosemon, 97300 Cayenne, French Guiana;
| | - Antoine Adenis
- Registre des Cancers de Guyane (RCan Guyane), Département Research, Innovation et Santé Publique (DRISP), Cayenne Hospital Center Andrée Rosemon, 97300 Cayenne, French Guiana; (L.M.I.); (Q.W.); (A.A.)
- Département Formation Recherche (DFR) en Santé, Université de Guyane, 97300 Cayenne, French Guiana;
- Centre d’Investigation Clinique (CIC, INSERM 1424), Cayenne Hospital Center Andrée Rosemon, 97300 Cayenne, French Guiana
| | - Mathieu Nacher
- Registre des Cancers de Guyane (RCan Guyane), Département Research, Innovation et Santé Publique (DRISP), Cayenne Hospital Center Andrée Rosemon, 97300 Cayenne, French Guiana; (L.M.I.); (Q.W.); (A.A.)
- Département Formation Recherche (DFR) en Santé, Université de Guyane, 97300 Cayenne, French Guiana;
- Centre d’Investigation Clinique (CIC, INSERM 1424), Cayenne Hospital Center Andrée Rosemon, 97300 Cayenne, French Guiana
| |
Collapse
|
2
|
Scott-Williams J, Hosein A, Akpaka P, Adidam Venkata CR. Epidemiology of Cervical Cancer in the Caribbean. Cureus 2023; 15:e48198. [PMID: 38054120 PMCID: PMC10694396 DOI: 10.7759/cureus.48198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/02/2023] [Indexed: 12/07/2023] Open
Abstract
Cervical cancer (CvC) is considered a preventable disease; however, in the Caribbean, it is still one of the fourth most common causes of death in women. Efforts to overcome obstacles to the treatment and control of this preventable disease are being made by several countries within the Caribbean. However, no health issue can be readily managed without first acquiring an understanding of the dynamics relating to its severity of impact reaching the target population, its clinical pathology, and the availability of treatment and/or preventative measures to control or halt its progression. To assess the status of CvC in the Caribbean, a review of the literature was conducted using PubMed. The Caribbean was defined in the review as comprising nations and islands whose coastlines are touched by the Caribbean Sea. This led to an assessment of the available literature on CvC for 33 Caribbean territories. The review showed a lack of published information on CvC and highlights the need for greater research. This also serves as a template for subsequent investigations.
Collapse
Affiliation(s)
- Jamie Scott-Williams
- Biomedical Engineering, The University of Trinidad and Tobago, Port of Spain, TTO
| | - Amalia Hosein
- Biomedical Engineering, The University of Trinidad and Tobago, Port of Spain, TTO
| | - Patrick Akpaka
- Pathology/Microbiology, The University of the West Indies, St. Augustine, TTO
| | | |
Collapse
|
3
|
Zarate AJ, Alonso FT, Garmendia ML, López-Köstner F. Increasing crude and adjusted mortality rates for colorectal cancer in a developing South American country. Colorectal Dis 2013; 15:47-51. [PMID: 22642835 DOI: 10.1111/j.1463-1318.2012.03110.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
AIM Colorectal cancer (CRC) is a major cause of cancer death worldwide. We examined temporal trends in death rates from colorectal cancer in Chile from 1983 to 2008. METHOD We analysed the mortality database in Chile from 1983 to 2008. Cases were selected using ICD-9/10 codes. We calculated mortality rates per 100,000 inhabitants according to sex, age group and type of cancer - colon (CC) or rectal (RC). The rates were adjusted by a direct method using the WHO-2000 standard population. Time trends were assessed with Prais-Winsten regression models. RESULTS There were 26,250 deaths from CRC (75.7% for CC). There was a higher frequency of deaths from CC (57.6%) in women than in men, who had a higher frequency of deaths from RC (51.3%). The crude CC mortality rate increased by 116% (from 3.6 to 7.8), while the overall RC rate increased by 71% (from 1.4 to 2.4). After adjusting for age, a significant increase in mortality rate was found for CC (coefficient 0.09, 95% CI 0.08-0.11, P < 0.001) and RC (coefficient 0.02, 95% CI 0.009-0.04, P = 0.002) in men. In women, this increase was significant for CC (coefficient 0.03, 95% CI 0.005-0.05; P = 0.02), but not for RC (coefficient -0.007, 95% CI -0.02 to 0.005, P = 0.23). CONCLUSION The crude mortality rate from CRC has doubled in Chile in this period. After adjustment of mortality rates, it appears that much of this increase is due to the aging population. However, part of this increase could be explained by other factors.
Collapse
Affiliation(s)
- A J Zarate
- Colorectal Unit, Clinica las Condes, Universidad de Chile, Santiago, Chile
| | | | | | | |
Collapse
|
4
|
Incidence and treatment of central nervous system tumors in Suriname. World Neurosurg 2012; 80:e79-83. [PMID: 22480978 DOI: 10.1016/j.wneu.2012.01.061] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2011] [Revised: 01/22/2012] [Accepted: 01/27/2012] [Indexed: 11/21/2022]
Abstract
OBJECTIVE To estimate the incidence of central nervous system (CNS) tumors in Suriname. METHODS A retrospective chart review was performed at the Academic Hospital Paramaribo and the State Health Insurance foundation. Patients receiving a diagnosis of CNS tumor in the period 2000-2010 were included in the study if a computed tomography scan or magnetic resonance imaging study was available. Demographic data and patient characteristics and disease variables were retrieved. RESULTS The study comprised 251 patients who met the inclusion criteria. The incidence of treated CNS tumors was 5 per 100,000 per year. There was a peak incidence in the 41-50 age group and a male-to-female ratio of 1:1.46. Of CNS tumors, 21% were gliomas, 26.7% were meningiomas, 4.7% were schwannomas, and 12.0% were pituitary adenomas. Suriname has a low glioma incidence compared with globally (40%-60% of CNS tumors globally). The incidence of pituitary adenoma was higher than expected. There are indications for a higher glioma and meningioma incidence in Javanese and a higher metastases incidence in Creoles. CONCLUSIONS The annual incidence of treated CNS tumors of 5 per 100,000 inhabitants in Suriname was in accordance with the expectation of an incidence of 3-6 per 100,000. Suriname is considered a country with a low cancer incidence. The differences found among various subgroups were too small to make definitive statements.
Collapse
|
5
|
van Leeuwaarde RS, Vrede MA, Henar F, Does R, Issa P, Burke E, Visser O, Rijmen F, Westermann AM. A nationwide analysis of incidence and outcome of breast cancer in the country of Surinam, during 1994-2003. Breast Cancer Res Treat 2011; 128:873-81. [PMID: 21340478 DOI: 10.1007/s10549-011-1404-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Accepted: 02/08/2011] [Indexed: 11/29/2022]
Abstract
In this study, we describe the incidence, treatment, and outcome of breast cancer (BC) during the period 1994-2003 in the South-American country of Surinam and compare these with those of BC in the Netherlands. Pathology reports and hospital charts from all BC cases diagnosed between 1994 and 2004 were retrieved from Surinam's single pathology laboratory and its five hospitals. Data on demographics, tumor characteristics, treatment, and follow-up were gathered. We compared our data to BC statistics of first generation immigrants from Surinam to the Netherlands. 421 patients were diagnosed with BC during the study period. The age-adjusted incidence rate was 26 per 100,000 compared to 65/100,000 in first generation Surinamese women in the Netherlands. The majority had a fairly advanced stage at presentation, with 60% of tumors larger than 2 cm, and 41.6% with lymph node involvement. Because of the absence of radiotherapy facilities, local treatment in most patients was radical mastectomy. Adjuvant hormonal therapy (51.6%) was administered more frequently than adjuvant chemotherapy (20.3%). A significant number of patients were lost to follow-up, resulting in a median follow-up duration of only 23 months. The 5-year overall survival was 79%. BC incidence in Surinam is low compared to that in the western world, but the advanced stage at diagnosis, the low utilization of systemic adjuvant therapy, and the inadequate follow-up may lead to poor outcomes. A number of steps are underway to improve the level of cancer care in Surinam.
Collapse
|
6
|
Ponz de Leon M, Rossi G, di Gregorio C, De Gaetani C, Rossi F, Ponti G, Pecone L, Pedroni M, Roncucci L, Pezzi A, Benatti P. Epidemiology of colorectal cancer: the 21-year experience of a specialised registry. Intern Emerg Med 2007; 2:269-79. [PMID: 18060471 DOI: 10.1007/s11739-007-0077-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2007] [Accepted: 07/18/2007] [Indexed: 12/21/2022]
Abstract
UNLABELLED Cancer registries can be viewed as one of the main strategies for improving our understanding of cancer, as they may reveal the importance of specific trends in cancer incidence and survival; in addition, the information obtained from the registries can be translated into preventive measures that might lead to a better control of neoplasms. A colorectal cancer registry was instituted in Northern Italy in 1984. The purpose of this study is to provide a description of the main findings observed in a 21-year period of continuous registration. RESULTS A total of 3951 malignancies of the large bowel were registered in 3817 patients, for a crude incidence rate of 75.1/100 000/year in men and 59.0 in women. Overall incidence (crude and age-adjusted) of colorectal tumours increased remarkably throughout the registration period. This increase was mainly due to early (Stage I and II) tumours and to lesions with lymph nodal involvement (Stage III). There was a tendency over time towards a progressive increase of colonic tumours, whereas the fraction of rectal neoplasms tended to decline. Colorectal cancer-specific survival increased significantly over time in each of the main TNM/Dukes classes (p<0.006 and <0.001 for Stage II and III tumours). Finally, surgery for colorectal tumours showed a tendency towards large operations (colectomy and hemicolectomy), which was parallel to a definite improvement of pathological staging. CONCLUSIONS Despite the increasing incidence of colorectal cancer, there are several reasons for cautious optimism. Most of the lesions are now diagnosed at an early stage, and this is associated with a significant increase of survival. The disease is undoubtedly cured better than in the past; the main challenge for future years is to achieve a sustained reduction of mortality for colorectal neoplasms.
Collapse
Affiliation(s)
- M Ponz de Leon
- Dipartimento di Medicine e Specialità Mediche Medicina I, Università di Modena e Reggio Emilia, Policlinico, Via del Pozzo 71, I-41100, Modena, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Rughooputh S, Eddoo R, Manraj S, Jeebun N, Greenwell P. Detection of human papillomavirus from archival tissues in cervical cancer patients in Mauritius. J Clin Virol 2005; 35:173-8. [PMID: 16115796 DOI: 10.1016/j.jcv.2005.03.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2003] [Revised: 03/11/2005] [Accepted: 03/15/2005] [Indexed: 11/26/2022]
Abstract
BACKGROUND Around half a million new cases of cervical cancer are diagnosed worldwide each year, accounting for almost 300,000 deaths. Development of cervical cancer can be multi-factorial, but high-risk human papillomaviruses (HPV) have been associated with the aetiology of cervical cancer. It is believed that HPV DNA integrates into the host DNA causing abnormal cell growth with cells becoming carcinogenic and spreading metastatically. In Mauritius, cervical cancer account for 65% of gynaecological cancers and 3.4% of the cervical cancers are diagnosed at the stage of carcinoma in situ. OBJECTIVES To determine the prevalence of HPV in histological samples from patients with cervical cancer in Mauritius. STUDY DESIGN DNA from archival cervical samples from a cohort of 65 patients suffering from cervical cancer and controls from Mauritius were tested for the presence of HPV using MY09/11 and GP5+/6+ primer sets. RESULTS In a cohort of 65 patients from Mauritius, diagnosed with cervical cancer in the year 2000, 19% of cervical histology sections were found to be positive for the presence of high-grade HPV, exclusively HPV18 using MY09 and MY11 primers. Only 15% of the Mauritian population is over 50 years of age, whereas 66% (35) of the diagnosed cases of cervical cancer were seen in patients above 50 years with 50% (5) affected with HPV. These findings suggest that for an infection with HPV to develop into cancer may take years if not decades. Differences were noted using two different primer sets, MY09/11 and GP5+/6+. The latter produce a much smaller amplicon (150bp) compared to the former ( approximately 450bp). Seven additional positive cases were detected with the GP5+/6+ primer set, resulting in an apparent prevalence of 32% as compared to the 19% seen with the MY09/11 primer set. This may indicate that some degradation of the target DNA has occurred during processing and storage of histological samples. CONCLUSION Using primer sets MY09/11 and GP5+/6+, only HPV type 18 was found in the Mauritian cohort with a prevalence of 32%.
Collapse
Affiliation(s)
- Sanjiv Rughooputh
- Molecular and Medical Microbiology Research Group, School of Biosciences, University of Westminster, 115, New Cavendish Street, London, W1 W6UW, UK.
| | | | | | | | | |
Collapse
|